MRNA Jun 2024 98.000 put
| Previous Close | 0.4800 |
| Open | 0.4600 |
| Bid | 0.1200 |
| Ask | 2.6600 |
| Strike | 98.00 |
| Expire Date | 2024-06-14 |
| Day's Range | 0.4600 - 0.4800 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 7 |
- Yahoo Finance Video
FDA considers updating COVID boosters, Novavax stock reacts
The US Food and Drug Administration (FDA) is set to vote on recommendations for updated COVID-19 booster shots as the KP.2 variant strain begins to spread across the US. Yahoo Finance Health Reporter Anjalee Khemlani joins Market Domination to discuss the impact this is having on vaccine makers, particularly Novavax (NVAX), whose stock has shot up in Monday's session. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Luke Carberry Mogan.
Insider MonkeyIs Moderna Inc. (NASDAQ:MRNA) the Top Gene Therapy Stock to Invest in Now?
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss whether Moderna, Inc. (NASDAQ:MRNA) is the top gene therapy stock to invest in now. Gene therapy involves treating illnesses by modifying, replacing, or supplementing faulty or missing genes responsible for a disease. This approach […]
ACCESSWIREModerna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in these ...
